Navigation Links
A brief explanation of Dopamine-Beta-hydroxylase (DBH) - SymPath(R) : In Vitro Diagnostic Test to distinguish anxious disorders from depressive disorders
Date:9/30/2010

BASEL, Switzerland, Sept. 30 /PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEET: MRES)(OTCQB:MRES) in acquiring licenses to commercialize 12 Neuro-biomarkers has first focused on SymPath(R) and is now ready to give you the opportunity to shed some light about this Neuro-biomarker of the Sympathetic Nervous System (SNS). Here is a peak into the research behind the Neuro-blood testing that will be available to all patients through their health system.

It is important to pinpoint that DBH was first described in 1955 and reviewed in 1965 by Kaufman & Friedman. In 1974, Geffen has described DBH as a biomarker of the SNS. At that moment, in the Journal of Neurochemistry, Roberge et al. (1976) have published that an inversed relationship occurs between the brain dopamine and serotonin content on a neuroanatomical basis. As in the brain, the noradrenergic and serotoninergic pathways are closed together at the level of the locus coereleus, the raphei nuclei and the brainstem, respectively (Roberge & Poirier, 1973, 1974) and that, to an increased dopamine content following the administration of L-DOPA in monkeys did not correspond to increased noradrenaline content within several neuroanatomical structures in the brain. Moreover, it was demonstrated that DBH was involved in anxiety and depression (Friedman et al., 1984).

In this respect, working with 15 to 18 different brain structures, the effects observed in the structures related to the motor system were different to those noted within the mesolimbic system - it was the starting point to understand how DBH is working to be the key enzyme in the noradrenaline synthesis.

The kinetic DBH enzyme activity and biochemical parameters were respectively studied in the brain, adrenals and blood of different species such as monkeys, cats, rats, rabbits, fish, mink, sheep and human beings using various stressful situations and several drugs. In this respect, Parkinson Disease, Alzheimer, Schizophrenia and stress related diseases were respectively studied working with catecholaminergic, serotoninergic and cholinergic pathways related to the motor system (monkeys), to the memory mechanisms (cats), learning disabilities (human beings), anorexia nervosa (human beings), bulimia (developing a model with rats in regards to people waiting for bypass surgery). As the relationship between the brain and the HPAS Axis is a key issue in stress related diseases, various stressful situations such as, cold exposure, immobilization and treadmill in rats, hypoxia in fish, a workload in a swimming pool in humans, food behaviours using cats, rabbits, rats, minks and fishes. Finally, in rats, the effects of spontaneously hypertensive state on DBH enzyme activity were compared to clinical data obtained from a group of post MI people.

DBH, the synthesising enzyme of noradrenaline from dopamine, is a copper and ascorbate dependent. Noradrenaline, a vasoconstrictor, is released within the blood from the SNS with DBH. Its biochemical and kinetic parameters were studied in brain, adrenals and serum (Fortin & Roberge, 1992) and in human beings to figure out how a commercial kit could be useful for different clinical purposes on a daily basis (US Patent (#5879902) and Canadian Patent (# 2204179)). In human beings, several studies were conducted involving different sexes, age, Rhesus factor, blood groups, seasonal variations, diurnal rhythms and endocrine functions..

In summary, noradrenaline, a vasoconstrictor, is released within the blood from the SNS with DBH. A commercial kit named SymPath(R) has been developed to quantitatively standardize the measurement kit of the specific activity of DBH released within the blood from the SNS. In this regards, the clinical data allow to distinguish anxious disorders from depressive disorders - that is a breakthrough in neurosciences.

Contact: Neuro-Biotech Corp. Dr Claude Poulin 41 61 500 05 16 info@neuro-agora.com www.neuro-biotechcorp.com


'/>"/>
SOURCE Neuro-Biotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
2. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
3. Hospital to Hold MRSA Briefing for Media and Community Leaders
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. CPR Data Debriefing by Hospital Responders Improves CPR Performance and Increases Initial Survival Rate Following Cardiac Arrest
6. Cardica to Host Investor Briefing on Revolutionizing Revascularization
7. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
8. Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site
9. Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program
10. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
11. World TB Day Senate Briefing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):